LIDDS presents at Redeye Fight Cancer Seminar
January 14, 2022 08:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will participate at Redeye Fight Cancer Seminar on January 20, 2022. Nina Herne, CEO of LIDDS, will present at 15.45 CET on...
LIDDS presenterar vid Redeye Fight Cancer seminarium
January 14, 2022 08:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) meddelade i dag att Nina Herne deltar vid Redeyes Fight Cancer seminarium den 20 januari 2022. LIDDS VD Nina Herne presenterar kl 15.45 den 20 januari 2022 på...
LIDDS announces successful stage 1 in R&D project
January 11, 2022 11:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the R&D project with Johnson & Johnson Enterprise Innovation Inc. has progressed into next phase. “On the back of a strong...
LIDDS tillkännager framgångsrikt slutförande av steg 1 i forskningssamarbete
January 11, 2022 11:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) tillkännagav i dag att forskningssamarbetet med Johnson & Johnson Enterprise Innovation Inc har fortsatt in i nästa fas. ”Genom ett starkt samarbete har...
LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
December 29, 2021 04:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both...
LIDDS tillkännager positiva topline resultat från den dos-eskalerande fas I studien av NanoZolid®-formulerad docetaxel
December 29, 2021 04:00 ET | LIDDS AB
UPPSALA, SVERIGE – LIDDS AB (publ) tillkännagav i dag att den systemiska exponeringen av docetaxel efter behandling av solida tumörer med NanoZolid®-formulerad docetaxel är låg och att studien visar...
LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
December 20, 2021 09:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Matthew Lindon has been appointed Chief Scientific Officer (CSO) of LIDDS AB. Matthew Lindon has over 20 years experience of drug discovery and...
LIDDS utser Matthew Lindon till Chief Scientific Officer
December 20, 2021 09:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) tillkännagav i dag att Matthew Lindon har utsetts till Chief Scientific Officer (CSO) för LIDDS AB. Matthew Lindon har över 20 års erfarenhet av drug discovery och...
logo.png
LIDDS patent covering the NanoZolid® production process granted in China
December 17, 2021 03:30 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in China. The...
logo.png
LIDDS Interim report January – September 2021
November 22, 2021 10:45 ET | LIDDS AB
JANUARY – SEPTEMBER 2021 Net sales amounted to MSEK 1.2 (0.0)Operating expenses amounted to MSEK -29,5 (-19,8)Profit/loss before and after tax amounted to MSEK -28.4 (-19.8)Earnings per share...